{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:59:10Z","timestamp":1792112350813,"version":"4.4.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T00:00:00Z","timestamp":1370304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T00:00:00Z","timestamp":1370304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1038\/nrclinonc.2013.84","type":"journal-article","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T13:05:17Z","timestamp":1370351117000},"page":"400-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":164,"title":["Clinical trials of human papillomavirus vaccines and beyond"],"prefix":"10.1038","volume":"10","author":[{"given":"Matti","family":"Lehtinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Dillner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,4]]},"reference":[{"key":"BFnrclinonc201384_CR1","unstructured":"International Agency for Research on Cancer. A Review of Human Carcinogens. Part B: Biological agents \/ IARC Working Group on the Evaluation of Carcinogenic Risks to Humans 255\u2013314 (Lyon, France, 2009)."},{"key":"BFnrclinonc201384_CR2","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","volume":"369","author":"J Paavonen","year":"2007","unstructured":"Paavonen, J.  et al. Efficacy of a prophylactic adjuvanted L1 VLP vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369, 2161\u20132170 (2007).","journal-title":"Lancet"},{"key":"BFnrclinonc201384_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","volume":"13","author":"M Lehtinen","year":"2012","unstructured":"Lehtinen, M.  et al. Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13, 89\u201399 (2012).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201384_CR4","doi-asserted-by":"crossref","unstructured":"The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356, 1915\u20131927 (2007).","DOI":"10.1056\/NEJMoa061741"},{"key":"BFnrclinonc201384_CR5","doi-asserted-by":"crossref","unstructured":"The FUTURE I\/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 341, c3493 (2010).","DOI":"10.1136\/bmj.c3493"},{"key":"BFnrclinonc201384_CR6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/ijc.20732","volume":"114","author":"SI Collins","year":"2005","unstructured":"Collins, S. I.  et al. Proximity of first intercourse to menarche and the risk of human papillomavirus infection: a longitudinal study. Int. J. Cancer 114, 498\u2013500 (2005).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201384_CR7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/aje\/kwf180","volume":"157","author":"RL Winer","year":"2003","unstructured":"Winer, R. L.  et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am. J. Epidemiol. 157, 218\u2013226 (2003).","journal-title":"Am. J. Epidemiol."},{"key":"BFnrclinonc201384_CR8","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1158\/1055-9965.EPI-04-0754","volume":"14","author":"SK Kjaer","year":"2005","unstructured":"Kjaer, S. K.  et al. Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol. Biomarkers Prev. 14, 1528\u20131533 (2005).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"BFnrclinonc201384_CR9","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/infdis\/173.6.1394","volume":"173","author":"J Dillner","year":"1996","unstructured":"Dillner, J.  et al. Seropositivies to human papillomavirus types 16, 18 and 33 capsids and to Chlamydia trachomastis are markers of sexual behaviour. J. Infect. Dis. 173, 1394\u20131398 (1996).","journal-title":"J. Infect. Dis."},{"key":"BFnrclinonc201384_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0002-9343(97)00177-0","volume":"102","author":"L Koutsky","year":"1997","unstructured":"Koutsky, L. Epidemiology of genital human papillomavirus infection. Am. J. Med. 102, 3\u20138 (1997).","journal-title":"Am. J. Med."},{"key":"BFnrclinonc201384_CR11","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1056\/NEJMoa053284","volume":"354","author":"RL Winer","year":"2006","unstructured":"Winer, R. L.  et al. Condom use and the risk of genital human papillomavirus infection in young women. N. Engl. J. Med. 354, 2645\u20132654 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201384_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0140-6736(10)61967-8","volume":"377","author":"MJ Wawer","year":"2011","unstructured":"Wawer, M. J.  et al. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet 377, 209\u2013218 (2011).","journal-title":"Lancet"},{"key":"BFnrclinonc201384_CR13","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.jcv.2004.12.006","volume":"32","author":"J Doorbar","year":"2005","unstructured":"Doorbar, J. The papillomavirus life cycle. J. Clin. Virol. 32, S7\u2013S15 (2005).","journal-title":"J. Clin. Virol."},{"key":"BFnrclinonc201384_CR14","doi-asserted-by":"publisher","first-page":"F24","DOI":"10.1016\/j.vaccine.2012.05.089","volume":"30","author":"AB Moscicki","year":"2012","unstructured":"Moscicki, A. B.  et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 30, F24\u2013F33 (2012).","journal-title":"Vaccine"},{"key":"BFnrclinonc201384_CR15","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1002\/ijc.25833","volume":"129","author":"GM Clifford","year":"2011","unstructured":"Clifford, G. M., Hoqwell-Jones, R. & Franceschi, S. Judging the carcinogenicity of human papillomavirus types by single\/multiple infection ratio in cervical cancer. Int. J. Cancer 129, 1702\u20131794 (2011).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201384_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1750-9378-4-8","volume":"4","author":"M Schiffman","year":"2009","unstructured":"Schiffman, M., Clifford, G. & Buonaguro, F. M. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect. Agents Cancer 4, 8 (2009).","journal-title":"Infect. Agents Cancer"},{"key":"BFnrclinonc201384_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ijc.27605","volume":"132","author":"G Halec","year":"2013","unstructured":"Halec, G.  et al. Biological activity of probable\/possible high-risk human papillomavirus types in cervical cancer. Int. J. Cancer 132, 62\u201371 (2013).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201384_CR18","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3109\/00365540903582426","volume":"42","author":"PB Namujju","year":"2010","unstructured":"Namujju, P. B.  et al. Risk of being seropositive for multiple human papillomavirus types among Finnish and Ugandan women. Scand. J. Infect. Dis. 42, 522\u2013526 (2010).","journal-title":"Scand. J. Infect. Dis."},{"key":"BFnrclinonc201384_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1750-9378-5-19","volume":"5","author":"M Stanley","year":"2010","unstructured":"Stanley, M. HPV\u2014immune response to infection and vaccination. Infect. Agent Cancer 5, 19 (2010).","journal-title":"Infect. Agent Cancer"},{"key":"BFnrclinonc201384_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1099\/0022-1317-80-2-391","volume":"80","author":"L Kjellberg","year":"1999","unstructured":"Kjellberg, L.  et al. Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J. Gen. Virol. 80, 391\u2013398 (1999).","journal-title":"J. Gen. Virol."},{"key":"BFnrclinonc201384_CR21","doi-asserted-by":"publisher","first-page":"e53067","DOI":"10.1371\/journal.pone.0053067","volume":"8","author":"SW Lin","year":"2013","unstructured":"Lin, S. W.  et al. HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS ONE 8, e53067 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrclinonc201384_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3109\/00365540903501608","volume":"42","author":"J Palmroth","year":"2010","unstructured":"Palmroth, J.  et al. Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes. Scand. J. Infect. Dis. 42, 379\u2013384 (2010).","journal-title":"Scand. J. Infect. Dis."},{"key":"BFnrclinonc201384_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/ijc.26362","volume":"131","author":"A Szarewski","year":"2012","unstructured":"Szarewski, A.  et al. Efficacy of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in women aged 15\u201325 years with and without serological evidence of previous exposure to HPV-16\/18. Int. J. Cancer 131, 106\u2013116 (2012).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201384_CR24","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/sj.bjc.6603653","volume":"96","author":"NW Bulkmans","year":"2007","unstructured":"Bulkmans, N. W.  et al. High-risk HPV type-specific clearance rates in cervical screening. Br. J. Cancer 96, 1419\u20131424 (2007).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc201384_CR25","first-page":"EP-412","volume-title":"28th International Papillomavirus Conference","author":"S Vanska","year":"2012","unstructured":"Vanska, S., Lehtinen, M. & Auranen, K. Explaining different HPV clearance rate estimates with different proportions of persistent infections [abstract]. 28th International Papillomavirus Conference EP-412 (2012)."},{"key":"BFnrclinonc201384_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jama.285.1.47","volume":"285","author":"T Anttila","year":"2001","unstructured":"Anttila, T.  et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 285, 47\u201351 (2001).","journal-title":"JAMA"},{"key":"BFnrclinonc201384_CR27","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/sti.2010.044354","volume":"87","author":"M Lehtinen","year":"2011","unstructured":"Lehtinen, M.  et al. Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex. Transm. Infect. 87, 372\u2013376 (2011).","journal-title":"Sex. Transm. Infect."},{"key":"BFnrclinonc201384_CR28","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1023\/B:CACO.0000003811.98261.3e","volume":"14","author":"M Plummer","year":"2003","unstructured":"Plummer, M.  et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case\u2014control study. Cancer Causes Control 14, 805\u2013814 (2003).","journal-title":"Cancer Causes Control"},{"key":"BFnrclinonc201384_CR29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/aje\/kwn354","volume":"169","author":"AS Kapeu","year":"2009","unstructured":"Kapeu, A. S.  et al. Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am. J. Epidemiol. 169, 480\u2013488 (2009).","journal-title":"Am. J. Epidemiol."},{"key":"BFnrclinonc201384_CR30","doi-asserted-by":"publisher","unstructured":"Luostarinen, T.  et al. Order of HPV\/Chlamydia infections and cervical high-grade precancer risk: a case-cohort study. Int. J. Cancer http:\/\/dx.doi.org\/10.1002\/ijc.28173.","DOI":"10.1002\/ijc.28173"},{"key":"BFnrclinonc201384_CR31","first-page":"323","volume-title":"Chlamydial Infections","author":"A Yl\u00e4-Outinen","year":"1990","unstructured":"Yl\u00e4-Outinen, A.  et al. in Chlamydial Infections (eds Stamm, W. E.  et al.) 323\u2013326 (Cambridge University Press, New York, 1990)."},{"key":"BFnrclinonc201384_CR32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ijc.20970","volume":"116","author":"I Silins","year":"2005","unstructured":"Silins, I.  et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int. J. Cancer 116, 110\u2013115 (2005).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201384_CR33","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10654-007-9180-8","volume":"22","author":"K Syrj\u00e4nen","year":"2007","unstructured":"Syrj\u00e4nen, K.  et al. Smoking is an independent risk factor for oncogenic human papillomavirus (HPV) infections but not for high-grade CIN. Eur. J. Epidemiol. 22, 723\u2013735 (2007).","journal-title":"Eur. J. Epidemiol."},{"key":"BFnrclinonc201384_CR34","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/00365540801995360","volume":"40","author":"A Simen-Kapeu","year":"2008","unstructured":"Simen-Kapeu, A.  et al. Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection. Scand. J. Infect. Dis. 40, 745\u2013751 (2008).","journal-title":"Scand. J. Infect. Dis."},{"key":"BFnrclinonc201384_CR35","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0140-6736(96)91417-8","volume":"347","author":"A Szarewski","year":"1996","unstructured":"Szarewski, A.  et al. Effect of smoking cessation on cervical lesion size. Lancet 347, 941\u2013943 (1996).","journal-title":"Lancet"},{"key":"BFnrclinonc201384_CR36","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1158\/1055-9965.EPI-06-0129","volume":"15","author":"H Trottier","year":"2006","unstructured":"Trottier, H.  et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol. Biomarkers Prev. 15, 1274\u20131280 (2006).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"BFnrclinonc201384_CR37","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1002\/ijc.22131","volume":"119","author":"M Lehtinen","year":"2006","unstructured":"Lehtinen, M.  et al. Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int. J. Cancer 119, 2612\u20132619 (2006).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201384_CR38","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1002\/ijc.24539","volume":"125","author":"M Kaasila","year":"2009","unstructured":"Kaasila, M.  et al. Population dynamics of serologically defined coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women. Int. J. Cancer 125, 2166\u20132172 (2009).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201384_CR39","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1158\/1055-9965.EPI-09-1235","volume":"19","author":"RP Insinga","year":"2010","unstructured":"Insinga, R. P.  et al. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol. Biomarkers Prev. 19, 1585\u20131594 (2010).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"BFnrclinonc201384_CR40","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/ijc.25675","volume":"128","author":"M Merikukka","year":"2011","unstructured":"Merikukka, M.  et al. Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. Int. J. Cancer 128, 1114\u20131119 (2011).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201384_CR41","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/infdis\/jir286","volume":"204","author":"S Vaccarella","year":"2011","unstructured":"Vaccarella, S.  et al. Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica. J. Infect. Dis. 204, 385\u2013390 (2011).","journal-title":"J. Infect. Dis."},{"key":"BFnrclinonc201384_CR42","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/infdis\/jir595","volume":"204","author":"S Vaccarella","year":"2011","unstructured":"Vaccarella, S.  et al. Clustering of human papillomavirus (HPV) types in the male genital tract: the HPV in men (HIM) study. J. Infect. Dis. 204, 1500\u20131504 (2011).","journal-title":"J. Infect. Dis."},{"key":"BFnrclinonc201384_CR43","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1086\/587698","volume":"197","author":"H Trottier","year":"2008","unstructured":"Trottier, H.  et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J. Infect. Dis. 197, 1436\u20131447 (2008).","journal-title":"J. Infect. Dis."},{"key":"BFnrclinonc201384_CR44","doi-asserted-by":"publisher","first-page":"8569","DOI":"10.1158\/0008-5472.CAN-10-0621","volume":"70","author":"H Trottier","year":"2010","unstructured":"Trottier, H.  et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res. 70, 8569\u20138577 (2010).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201384_CR45","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.vaccine.2010.12.090","volume":"29","author":"S Calabro","year":"2011","unstructured":"Calabro, S.  et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29, 1812\u20131823 (2011).","journal-title":"Vaccine"},{"key":"BFnrclinonc201384_CR46","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/j.molimm.2010.03.010","volume":"47","author":"K Serre","year":"2010","unstructured":"Serre, K.  et al. IL-4 directs both CD4 and CD8 T cells to produce Th2 cytokines in vitro, but only CD4 T cells produce these cytokines in response to alum-precipitated protein in vivo. Mol. Immunol. 47, 1914\u20131922 (2010).","journal-title":"Mol. Immunol."},{"key":"BFnrclinonc201384_CR47","doi-asserted-by":"publisher","first-page":"5407","DOI":"10.1016\/j.vaccine.2010.06.018","volume":"28","author":"JG Dauner","year":"2010","unstructured":"Dauner, J. G., Pan, Y., Hildesheim, A., Harro, C. & Pinto, L. A. Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine 28, 5407\u20135413 (2010).","journal-title":"Vaccine"},{"key":"BFnrclinonc201384_CR48","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","volume":"24","author":"SL Giannini","year":"2006","unstructured":"Giannini, S. L.  et al. Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24, 5937\u20135949 (2006).","journal-title":"Vaccine"},{"key":"BFnrclinonc201384_CR49","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","volume":"40","author":"C Pedersen","year":"2007","unstructured":"Pedersen, C.  et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J. Adolesc. Health 40, 564\u2013571 (2007).","journal-title":"J. Adolesc. Health"},{"key":"BFnrclinonc201384_CR50","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/ijc.23260","volume":"122","author":"G Perez","year":"2008","unstructured":"Perez, G.  et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int. J. Cancer 122, 1311\u20131318 (2008).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201384_CR51","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.vaccine.2007.11.043","volume":"26","author":"CM Wheeler","year":"2008","unstructured":"Wheeler, C. M.  et al. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6\/11\/16\/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 26, 686\u2013696 (2008).","journal-title":"Vaccine"},{"key":"BFnrclinonc201384_CR52","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jadohealth.2008.10.002","volume":"44","author":"T Pet\u00e4j\u00e4","year":"2009","unstructured":"Pet\u00e4j\u00e4, T.  et al. Immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in healthy boys aged 10\u201318 years. J. Adolesc. Health 44, 33\u201341 (2009).","journal-title":"J. Adolesc. Health"},{"key":"BFnrclinonc201384_CR53","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/INF.0b013e3181e28e6e","volume":"29","author":"T Vesikari","year":"2010","unstructured":"Vesikari, T.  et al. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6\/11\/16\/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr. Infect. Dis. J. 29, 314\u2013318 (2010).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"BFnrclinonc201384_CR54","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/j.ygyno.2007.07.075","volume":"107","author":"AR Giuliano","year":"2007","unstructured":"Giuliano, A. R. Human papillomavirus vaccination in males. Gynecol. Oncol. 107, S24\u2013S26 (2007).","journal-title":"Gynecol. Oncol."},{"key":"BFnrclinonc201384_CR55","volume-title":"Epidemiological Study of Tobacco Use and Human Papillomavirus","author":"A Kapeu","year":"2009","unstructured":"Kapeu, A. Epidemiological Study of Tobacco Use and Human Papillomavirus Thesis, University of Tampere (2009)."},{"key":"BFnrclinonc201384_CR56","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","volume":"95","author":"LL Villa","year":"2006","unstructured":"Villa, L. L.  et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer 95, 1459\u20131466 (2006).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc201384_CR57","doi-asserted-by":"publisher","first-page":"390","DOI":"10.4161\/hv.18865","volume":"3","author":"CM Roteli-Martins","year":"2012","unstructured":"Roteli-Martins, C. M.  et al. Sustained immunogenicity and efficacy of the HPV-16\/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum. Vaccin. Immunother. 3, 390\u2013397 (2012).","journal-title":"Hum. Vaccin. Immunother."},{"key":"BFnrclinonc201384_CR58","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","volume":"25","author":"SE Olsson","year":"2007","unstructured":"Olsson, S. E.  et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine. Vaccine 25, 4931\u20134939 (2007).","journal-title":"Vaccine"},{"key":"BFnrclinonc201384_CR59","doi-asserted-by":"publisher","first-page":"431","DOI":"10.4161\/hv.19179","volume":"4","author":"C Roberts","year":"2012","unstructured":"Roberts, C., Swoyer, R. & Bryan, J. Evaluation of the HPV 18 antibody response in Gardasil\u00ae vaccinees after 48 mo using a pseudovirion neutralization assay. Hum. Vaccin. Immunother. 4, 431\u2013434 (2012).","journal-title":"Hum. Vaccin. Immunother."},{"key":"BFnrclinonc201384_CR60","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.1016\/j.vaccine.2008.09.073","volume":"26","author":"EA Joura","year":"2008","unstructured":"Joura, E. A.  et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26, 6844\u20136851 (2008).","journal-title":"Vaccine"},{"key":"BFnrclinonc201384_CR61","first-page":"705","volume":"10","author":"MH Einstein","year":"2010","unstructured":"Einstein, M. H.  et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18\u201345 years. Hum. Vaccin. 10, 705\u2013719 (2010).","journal-title":"Hum. Vaccin."},{"key":"BFnrclinonc201384_CR62","doi-asserted-by":"publisher","first-page":"8285","DOI":"10.1016\/j.vaccine.2011.09.021","volume":"29","author":"E Draper","year":"2011","unstructured":"Draper, E.  et al. Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine 29, 8285\u20138290 (2011).","journal-title":"Vaccine"},{"key":"BFnrclinonc201384_CR63","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1002\/ijc.25887","volume":"129","author":"T Pet\u00e4j\u00e4","year":"2011","unstructured":"Pet\u00e4j\u00e4, T.  et al. Long-term persistence of systemic and mucosal immune response to HPV-16\/18 ASO4-adjuvanted vaccine in preteen\/adolescents girls and young women. Int. J. Cancer 129, 2147\u20132157 (2011).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201384_CR64","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/bjc.2013.22","volume":"108","author":"J Cuzick","year":"2013","unstructured":"Cuzick, J.  et al. Comparing the performance of six human papillomavirus tests in a screening population. Br. J. Cancer 108, 908\u2013903 (2013).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc201384_CR65","unstructured":"Szarewski, A.  et al. Efficacy of the HPV-16\/18 AS04-adjuvanted vaccine against HPV types associated with genital warts [abstract]. EUROGIN 2012 Congress SS 12\u20132 (2012)."},{"key":"BFnrclinonc201384_CR66","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1056\/NEJMoa0909537","volume":"364","author":"AR Giuliano","year":"2011","unstructured":"Giuliano, A. R.  et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N. Engl. J. Med. 364, 401\u2013411 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201384_CR67","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1086\/656320","volume":"202","author":"T Wilkin","year":"2010","unstructured":"Wilkin, T.  et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J. Infect. Dis. 202, 1246\u20131253 (2010).","journal-title":"J. Infect. Dis."},{"key":"BFnrclinonc201384_CR68","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/jnci\/djp534","volume":"102","author":"N Mu\u00f1oz","year":"2010","unstructured":"Mu\u00f1oz, N.  et al. Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women. J. Natl Cancer Inst. 102, 325\u2013339 (2010).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201384_CR69","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/pgp.0b013e31805152ab","volume":"26","author":"JD Carreon","year":"2007","unstructured":"Carreon, J. D.  et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int. J. Gynecol. Pathol. 26, 441\u2013446 (2007).","journal-title":"Int. J. Gynecol. Pathol."},{"key":"BFnrclinonc201384_CR70","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/AOG.0b013e31818f5008","volume":"113","author":"PE Castle","year":"2009","unstructured":"Castle, P. E., Schiffman, M., Wheeler, C. M. & Solomon, D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet. Gynecol. 113, 18\u201325 (2009).","journal-title":"Obstet. Gynecol."},{"key":"BFnrclinonc201384_CR71","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","volume":"2","author":"SK Kjaer","year":"2009","unstructured":"Kjaer, S. K.  et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev. Res. (Phila.) 2, 868\u2013878 (2009).","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"BFnrclinonc201384_CR72","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1002\/ijc.27971","volume":"132","author":"MM Rana","year":"2013","unstructured":"Rana, M. M.  et al. Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: cancer registry-based follow-up. Int. J. Cancer 132, 2833\u20132838 (2013).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201384_CR73","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","volume":"377","author":"JM Brotherton","year":"2011","unstructured":"Brotherton, J. M.  et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 377, 2085\u20132092 (2011).","journal-title":"Lancet"},{"issue":"Suppl. 3","key":"BFnrclinonc201384_CR74","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.vaccine.2006.05.109","volume":"24","author":"M Lehtinen","year":"2006","unstructured":"Lehtinen, M.  et al. Chapter 28: Studies to assess long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 24 (Suppl. 3), 233\u2013241 (2006).","journal-title":"Vaccine"},{"key":"BFnrclinonc201384_CR75","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","volume":"365","author":"JM Palefsky","year":"2011","unstructured":"Palefsky, J. M.  et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med. 365, 1576\u20131585 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201384_CR76","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S1470-2045(11)70213-3","volume":"12","author":"AR Kreimer","year":"2011","unstructured":"Kreimer, A. R.  et al. Efficacy of a bivalent HPV 16\/18 vaccine against anal HPV16\/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol. 12, 862\u2013870 (2011).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201384_CR77","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S0140-6736(11)60678-8","volume":"378","author":"HJ Larson","year":"2011","unstructured":"Larson, H. J., Cooper, L. Z., Eskola, J., Katz, S. L. & Ratzan, S. Addressing the vaccine confidence gap. Lancet 378, 526\u2013535 (2011).","journal-title":"Lancet"},{"key":"BFnrclinonc201384_CR78","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJMoa032665","volume":"350","author":"A Hviid","year":"2004","unstructured":"Hviid, A., Steffeld, M., Wohlfahrt, J. & Melbye, M. Childhood vaccination and type 1 diabetes. N. Engl. J. Med. 350, 1398\u20131404 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201384_CR79","doi-asserted-by":"publisher","first-page":"e2794","DOI":"10.1136\/bmj.e2794","volume":"344","author":"B Pasternak","year":"2012","unstructured":"Pasternak, B.  et al. Vaccination against pandemic A\/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ 344, e2794 (2012).","journal-title":"BMJ"},{"key":"BFnrclinonc201384_CR80","doi-asserted-by":"publisher","first-page":"c712","DOI":"10.1136\/bmj.c712","volume":"340","author":"S Wacholder","year":"2010","unstructured":"Wacholder, S.  et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ 340, c712 (2010).","journal-title":"BMJ"},{"key":"BFnrclinonc201384_CR81","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1365-2796.2011.02467.x","volume":"271","author":"C Chao","year":"2010","unstructured":"Chao, C.  et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J. Intern. Med. 271, 193\u2013203 (2010).","journal-title":"J. Intern. Med."},{"key":"BFnrclinonc201384_CR82","doi-asserted-by":"publisher","first-page":"b3884","DOI":"10.1136\/bmj.b3884","volume":"339","author":"JJ Kim","year":"2009","unstructured":"Kim, J. J. & Goldie, S. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 339, b3884 (2009).","journal-title":"BMJ"},{"key":"BFnrclinonc201384_CR83","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1371\/journal.pmed.0030138","volume":"3","author":"RV Barnabas","year":"2006","unstructured":"Barnabas, R. V.  et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential of vaccination: mathematical modelling analyses. PLoS Med. 3, e138 (2006).","journal-title":"PLoS Med."},{"key":"BFnrclinonc201384_CR84","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1071\/SH07042","volume":"4","author":"DG Regan","year":"2007","unstructured":"Regan, D. G., Philp, D. J., Hocking, J. S. & Law, M. G. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sex. Health 4, 147\u2013163 (2007).","journal-title":"Sex. Health"},{"key":"BFnrclinonc201384_CR85","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2217\/14750708.5.3.289","volume":"5","author":"M Lehtinen","year":"2008","unstructured":"Lehtinen, M., French, K. M., Dillner, J., Paavonen, J. & Garnett, G. Sound implementation of human papillomavirus vaccination as a community-randomized trial. Therapy 5, 289\u2013294 (2008).","journal-title":"Therapy"},{"key":"BFnrclinonc201384_CR86","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1001\/jama.284.20.2643","volume":"284","author":"H Peltola","year":"2000","unstructured":"Peltola, H.  et al. Mumps and rubella eliminated from Finland. JAMA 284, 2643\u20132647 (2000).","journal-title":"JAMA"},{"key":"BFnrclinonc201384_CR87","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1136\/bmj.39541.534109.BE","volume":"336","author":"L Brabin","year":"2008","unstructured":"Brabin, L.  et al. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ 336, 1056\u20131058 (2008).","journal-title":"BMJ"},{"key":"BFnrclinonc201384_CR88","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1002\/ijc.24476","volume":"125","author":"M Lehtinen","year":"2009","unstructured":"Lehtinen, M. & Paavonen, J. Impact of human papillomavirus vaccination depends on effective vaccination strategy. Int. J. Cancer 125, 1490\u20131491 (2009).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201384_CR89","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1136\/medethics-2011-100090","volume":"38","author":"E Malmqvist","year":"2012","unstructured":"Malmqvist, E., Natunen, K., Lehtinen, M. & Helgesson, G. Just implemention of human papillomavirus vaccination. J. Med. Ethics 38, 247\u2013249 (2012).","journal-title":"J. Med. Ethics"},{"key":"BFnrclinonc201384_CR90","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1136\/bmj.319.7223.1462","volume":"319","author":"T Panagiotopoulos","year":"1999","unstructured":"Panagiotopoulos, T., Antoniadou, I. & Valassi-Adam, E. Increase in congenital rubella occurrence in Greece: retrospective survey and systematic review. BMJ 319, 1462\u20131467 (1999).","journal-title":"BMJ"},{"key":"BFnrclinonc201384_CR91","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jadohealth.2010.04.006","volume":"47","author":"R Rouzier","year":"2010","unstructured":"Rouzier, R. & Giordanella, J. P. Coverage and compliance of human papilloma virus vaccines in Paris: demonstration of low compliance with non-school-based approaches. J. Adolesc. Health 47, 237\u2013241 (2010).","journal-title":"J. Adolesc. Health"},{"key":"BFnrclinonc201384_CR92","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.ypmed.2010.11.006","volume":"52","author":"R Taylor","year":"2011","unstructured":"Taylor, R., Hariri, S., Sterberg, M., Dunne, E. F. & Markowitz, L. E. Human papillomavirus vaccine coverage in the United States: National Health and Nutrition Examination Survey. Prev. Med. 52, 398\u2013400 (2011).","journal-title":"Prev. Med."},{"key":"BFnrclinonc201384_CR93","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJM200104123441503","volume":"344","author":"J Mork","year":"2001","unstructured":"Mork, J.  et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 344, 1125\u20131131 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201384_CR94","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1002\/cncr.20998","volume":"103","author":"CH Shiboski","year":"2005","unstructured":"Shiboski, C. H., Schmidt, B. L. & Jordan, R. C. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20\u201344 years. Cancer 103, 1843\u20131849 (2005).","journal-title":"Cancer"},{"key":"BFnrclinonc201384_CR95","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/ijc.24339","volume":"125","author":"A N\u00e4sman","year":"2009","unstructured":"N\u00e4sman, A.  et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int. J. Cancer 125, 362\u2013366 (2009).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201384_CR96","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/sj.bjc.6603175","volume":"95","author":"DH Brewster","year":"2006","unstructured":"Brewster, D. H. & Bhatti, L. A. Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975\u20132002. Br. J. Cancer 95, 87\u201390 (2006).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc201384_CR97","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1071\/SH10020","volume":"7","author":"AE Grulich","year":"2010","unstructured":"Grulich, A. E., Jin, F., Conway, E. L., Stein, A. N. & Hocking, J. Cancers attributable to human papillomavirus infection. Sex. Health 7, 244\u2013252 (2010).","journal-title":"Sex. Health"},{"key":"BFnrclinonc201384_CR98","doi-asserted-by":"publisher","first-page":"995","DOI":"10.4161\/onci.20011","volume":"1","author":"M Lehtinen","year":"2012","unstructured":"Lehtinen, M. & Paavonen, J. Sound efficacy of prophylactic HPV vaccination: basics and implications. Oncoimmunology 1, 995\u2013996 (2012).","journal-title":"Oncoimmunology"},{"key":"BFnrclinonc201384_CR99","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1056\/NEJMoa020586","volume":"347","author":"LA Koutsky","year":"2002","unstructured":"Koutsky, L. A.  et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1647\u20131651 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201384_CR100","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4161\/hv.7.2.13690","volume":"7","author":"B Romanowski","year":"2011","unstructured":"Romanowski, B. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum. Vaccin. 7, 161\u2013169 (2011).","journal-title":"Hum. Vaccin."},{"key":"BFnrclinonc201384_CR101","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1002\/ijc.27586","volume":"131","author":"J Palmroth","year":"2012","unstructured":"Palmroth, J.  et al. Occurrence of vaccine and non-vaccine HPV types in adolescent Finnish females 4 years post-vaccination. Int. J. Cancer 131, 2832\u20132838 (2012).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201384_CR102","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1158\/1055-9965.EPI-12-1003","volume":"22","author":"A S\u00f6derlund-Strand","year":"2013","unstructured":"S\u00f6derlund-Strand, A. & Dilner, J. High-throughput monitoring of human papillomavirus type distribution. Cancer Epidemiol. Biomarkers Prev. 22, 242\u2013250 (2013).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"BFnrclinonc201384_CR103","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(10)70225-5","volume":"11","author":"B Donovan","year":"2011","unstructured":"Donovan, B.  et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect. Dis. 11, 39\u201344 (2011).","journal-title":"Lancet Infect. Dis."},{"key":"BFnrclinonc201384_CR104","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/jnci\/djt032","volume":"105","author":"A Leval","year":"2013","unstructured":"Leval, A.  et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J. Natl Cancer Inst. 105, 469\u2013474 (2013).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201384_CR105","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/OLQ.0b013e31827bd66b","volume":"40","author":"L Baandrup","year":"2013","unstructured":"Baandrup, L.  et al. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex. Transm. Dis. 40, 130\u2013135 (2013).","journal-title":"Sex. Transm. Dis."},{"key":"BFnrclinonc201384_CR106","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1086\/425271","volume":"191","author":"GP Garnett","year":"2005","unstructured":"Garnett, G. P. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J. Infect. Dis. 191, S97\u2013S106 (2005).","journal-title":"J. Infect. Dis."},{"key":"BFnrclinonc201384_CR107","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/QCO.0b013e328334c0e1","volume":"1","author":"M Stanley","year":"2010","unstructured":"Stanley, M. Prospects for new HPV vaccines. Curr. Opin. Infect. Dis. 1, 70\u201375 (2010).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"BFnrclinonc201384_CR108","doi-asserted-by":"publisher","first-page":"e39741","DOI":"10.1371\/journal.pone.0039741","volume":"7","author":"K Nieto","year":"2012","unstructured":"Nieto, K.  et al. Development of AAVLP (HPV16\/31L2) particles as broadly protective HPV vaccine candidate. PLoS ONE 7, e39741 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrclinonc201384_CR109","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2159-8290.CD-11-0131","volume":"1","author":"R Herrero","year":"2011","unstructured":"Herrero, R.  et al. Prevention of persistent human papillomavirus infection by an HPV16\/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov. 1, 408\u2013419 (2011).","journal-title":"Cancer Discov."},{"key":"BFnrclinonc201384_CR110","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","volume":"13","author":"CM Wheeler","year":"2012","unstructured":"Wheeler, C. M.  et al. Efficacy of the HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13, 100\u2013110 (2012).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201384_CR111","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1086\/597307","volume":"199","author":"DR Brown","year":"2009","unstructured":"Brown, D. R.  et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years. J. Infect. Dis. 199, 926\u2013935 (2009).","journal-title":"J. Infect. Dis."}],"updated-by":[{"DOI":"10.1038\/nrclinonc.2014.204","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T00:00:00Z","timestamp":1415664000000}}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2013.84.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2013.84","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2013.84.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T09:19:25Z","timestamp":1744276765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2013.84"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,4]]},"references-count":111,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["BFnrclinonc201384"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2013.84","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/nrclinonc.2014.204","asserted-by":"object"}]},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,4]]},"assertion":[{"value":"4 June 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2014","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of this Review article originally published online and in print in the July 2013 issue of <i>Nature Reviews Clinical Oncology<\/i> there were errors in the clinical data presented in Tables 2, 3 and 5. In addition, reference 68 should have been cited to support data in Table 2, and the efficacy of the bivalent vaccine in adenocarcinoma in situ was 76.9% rather than 100% as originally reported in the main text on page 405. The errors have been corrected in the HTML and PDF versions of the article.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M. Lehtinen and J. Dillner have received grants to their institutions to conduct clinical trials and follow-up studies of HPV vaccines from Merck & Co, GlaxoSmithKline Biologicals (ML) and Sanofi-Pasteur MSD (J. Dillner). J. Dillner has participated in the steering group of a phase III vaccination trial sponsored by Merck.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}